Home Check-Ups for DMD: a new study tests if Tele-Assessments are reliable
NCT ID NCT06295718
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether doctors can accurately assess physical function and quality of life in children with Duchenne muscular dystrophy (DMD) through video calls. Twenty ambulatory patients aged 5-18 completed timed tests and questionnaires remotely. The goal was to see if tele-assessment is a valid and reliable alternative to in-person visits, which could ease the travel burden on families.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could allow DMD patients to be evaluated from home, reducing travel stress and saving time for families.
- What could go wrong
- This is a small, completed study with only 20 participants, so results may not apply to all patients. It tests assessment methods, not a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
İstanbul University - Cerrahpaşa
Istanbul, Istanbul, 34758, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lower steroid dose preserve strength in young boys with DMD?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy